Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 76 Paragraph 2 â 3: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 5: | Line 5: | ||
Paragraph 2 â 3 | Paragraph 2 â 3 | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00046-Ser-sSc ++ TAG-00231-Per-ung ++ TAG-00208-Dev-ers ++ TAG-00017-Spo-die | ||
| | |RefModule=5 | ||
| | |RefUnit=5.3.5 | ||
}} | }} | ||
| Line 15: | Line 15: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 5 â Unit 5.3.5 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 32: | Line 35: | ||
| Â | | Â | ||
|- | |- | ||
! Tags | ! Tags | ||
| Â | | [[Glossary:TAG-00046-Ser-sSc|Serious adverse event]], [[Glossary:TAG-00231-Per-ung|Performance study]], [[Glossary:TAG-00208-Dev-ers|Device deficiency]], [[Glossary:TAG-00017-Spo-die|Sponsor]] | ||
|- | |||
| Â | |||
|- | |||
| Â | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 |
| Validity area | EU |
| Scope(s) | IVD |
| Document name | Regulation (EU) 2017/746 - in vitro diagnostic medical devices |
| Version / Revision | 20-Mar-2023 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 5 â Unit 5.3.5 |
| Scope | IVD |
| Document part | Article 76
Paragraph 2 â 3 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Serious adverse event, Performance study, Device deficiency, Sponsor |
| Comment | Sponsor reporting obligations in performance studies (2) |
Content
Recording and reporting of adverse events that occur during performance studies
2. The sponsor shall report without delay to all Member States in which a performance study is being conducted all of the following by means of the electronic system referred to in Article 69:
(a) any serious adverse event that has a causal relationship with the device, the comparator or the study procedure or where such causal relationship is reasonably possible;
(b) any device deficiency that might have led to a serious adverse event if appropriate action had not been taken, intervention had not occurred, or circumstances had been less fortunate;
(c) any new findings in relation to any event referred to in points (a) and (b).
The period for reporting shall take account of the severity of the event. Where necessary to ensure timely reporting, the sponsor may submit an initial report that is incomplete followed up by a complete report.
Upon request by any Member State in which the performance study is being conducted, the sponsor shall provide all information referred to in paragraph 1.
3. The sponsor shall also report to the Member States in which the performance study is being conducted any event referred to in paragraph 2 of this Article that occurred in third countries in which a performance study is performed under the same clinical performance study plan as the one applying to a performance study covered by this Regulation by means of the electronic system referred to in Article 69.
